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The Guidelines Project of the Associação Médica Brasileira 
(AMB) and of the Conselho Federal de Medicina (CFM) 
began in 2000 with specialist societies participating in 
the preparation of the texts. The guidelines are based on 
research and contain solid advice on the diagnosis, therapy, 
and prevention of diseases. Grounded in evidence-based 
medicine, they seek to answer specific or crucial questions 
regarding the disease. A review of the literature is performed 
and, using pre-established criteria, studies on the disease are 
selected and graded according to their characteristics and 
type. Randomized clinical trials and meta-analyses have the 
highest value (A). Second in importance are observational and 
clinical studies (B), then case reports and case series (C), and 
finally, publications of consensuses and opinions (D). Due to 
the methodology employed, current systematic reviews are 
clearly more relevant when compared to those written in the 
past. Historically, reviews were much more based on personal 
opinions and subject to the author’s interest, that is, more 
concerned with the individual point of view and based on 
personal experience.1
The Associação Brasileira de Hematologia, Hemoterapia 
e Terapia Celular (ABHH) began to participate effectively in 
the development of the guidelines of the AMB in 2009, with 
contributions by several experts as shown in Table 1; previously, 
the collection was limited, with fewer themes. After 2012, 
guidelines on several diseases were completed and published 
in the Revista Brasileira de Hematologia e Hemoterapia 
(RBHH); chronic myelogenous leukemia,2 multiple myeloma,3 
and diagnosis4 and treatment of immune thrombocytopenic 
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purpura.5 It is also important to quote other systematic reviews 
published in the RBHH, such as preventive practices in long-
term hematopoietic stem cell transplantation survivors, with 
the participation of experts from several different countries.6 
The consensus of the Sociedade Brasileira de Transplante de 
Medula Óssea (SBTMO) produced the famous ‘Pink Book’; this 
was rounded out with two publications on transplantation in 
acute myeloid leukemia7 and  autoimmune diseases.8
Theme Reference
Severe aplastic anemia AMB
Prophylaxis of venous thromboembolism in clinical I 
patients
 
AMB
Prophylaxis of venous thromboembolism in clinical II 
patients
 
AMB
Prophylaxis of venous thromboembolism in clinical III 
patients
 
AMB
Chronic myelogenous leukemia (2)
Multiple myeloma (3)
Immune thrombocytopenic purpura - diagnosis (4)
Immune thrombocytopenic purpura - treatment (5)
Acute promyelocytic leukemia (12)
 AMB: Associação Médica Brasileira.
Table 1 - Guidelines published on hematological 
diseases.
Acute promyelocytic leukemia (APL) has well-defined 
clinical, cytogenetic, and morphological characteristics; it 
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encompasses 10% to 15% of all myeloid-type leukemias. Its 
molecular bases are well defined, with different variations 
influencing the treatment of patients.9 The results, as 
reported by the International Consortium on APL, established 
the treatment strategies and the conduct for the disease in 
developing countries.10,11
The guidelines for the diagnosis and treatment of APL12 
are published in this issue of the RBHH, the first in 2014, 
thereby adding to those already published. Hopefully, this will 
stimulate other experts to continue this hard work, aiming to 
contribute to medical practice and to solidify the knowledge on 
the diagnoses and treatment of hematologic diseases.
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